3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
29
Burkitt Lymphoma
23
Multiple Myeloma
21
Lymphoma, Large B-Cell, Diffuse
21
Leukemia, Myeloid, Acute
18
Lymphoma, Non-Hodgkin
16
Myelodysplastic Syndromes
15
Lymphoma, B-Cell
14
Lymphoma
14
Recurrence
11
Ovarian Neoplasms
11
Lymphoma, Follicular
11
Hodgkin Disease
11
Triple Negative Breast Neoplasms
10
Neoplasms
9
Lymphoma, Mantle-Cell
9
Leukemia, Lymphocytic, Chronic, B-Cell
9
Breast Neoplasms
9
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Pancreatic Neoplasms
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Leukemia
8
Hematologic Neoplasms
7
Sarcoma
6
Osteosarcoma
6
Leukemia, Myelomonocytic, Chronic
6
Colorectal Neoplasms
6
Lymphoma, B-Cell, Marginal Zone
5
Leukemia, Biphenotypic, Acute
5
Graft vs Host Disease
5
Interventions
lifileucel
1
fludarabine phosphate
1
fludarabine
1
Nivolumab
1
Iodized Oil
1
Ethiodized Oil
1
Cyclophosphamide
1
Carmustine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uveal Melanoma
×
Cyclophosphamide
×
30 days
×
Clear all
NCT07627698
2026-06-04
DUET-MEL
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled